10 Years, 69,000 Cases, $5.5 Billion: The End of the J&J Talc Controversy Explained

Add as a preferred source on Google

For a decade, women who used Johnson's Baby Powder and later developed ovarian cancer fought the same company in courtroom after courtroom. On Monday, that fight moved decisively towards a close.

Photo Credit: Chat GPT

Johnson & Johnson said it would pay $5.5 billion to settle tens of thousands of lawsuits alleging its baby powder and other talc products cause ovarian cancer, in a settlement covering nearly all remaining claims and aimed at ending years of contentious litigation. The settlement covers about 69,000 cases consolidated in federal court in New Jersey, along with related cases in state court, totalling 99.75 per cent of the remaining talc claims against the company.

A Decade Of Courtrooms, Bankruptcy Attempts And Appeals

The road to this settlement was not straight. J&J had a mixed record in talc trials before its bankruptcy attempts, including a multibillion-dollar verdict in favour of 22 women who said baby powder caused their ovarian cancer, alongside outright wins and reduced appellate verdicts. Litigation resumed only in March 2025, after being paused for more than three years while J&J repeatedly tried, and failed, to resolve the lawsuits through a shell company's bankruptcy.

Just last week, J&J won a significant court victory when a federal judge cast doubt on individual plaintiffs' ability to prove that talc specifically caused their ovarian cancer. Even so, the company chose to settle. Erik Haas, J&J's vice-president of litigation, called the claims "meritless" but said the company was willing to settle in order to get closure. "While we are confident the company would have ultimately prevailed with further litigation, as it has in the vast majority of cases tried to date, this resolution allows the company to put this matter behind it," Haas said, adding that J&J wanted to remain focused on its mission to develop medicines and devices that save lives.

What Happens Next For Claimants

The deal must still be approved by the judge overseeing the federal litigation, and requires acceptance from 95 per cent of ovarian cancer claimants in state or federal court before it becomes final. J&J expects to pay $3 billion in 2027, with further payments following in 2028. Unlike J&J's earlier bankruptcy proposals, this agreement covers only existing claims - it does not address future lawsuits.

Plaintiffs' law firms have called it one of the largest products liability settlements in US history, set to provide a minimum of $5.5 billion to roughly 70,000 women and their families, with compensation determined through a tiered grid based on objective claim criteria. Because the deal is uncapped, its final value could climb higher depending on participation.

J&J has long denied that its talc products caused cancer, maintaining that talc was safe and did not contain asbestos, though it stopped selling talc-based baby powder in the US in 2020, switching to a cornstarch formula. A record case is also currently under way in the UK against the company.

Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.